Looking beyond Proteomics, Biodesix Inks Deal with Inivata to Develop NGS Tests for Lung Cancer | GenomeWeb

NEW YORK(GenomeWeb) – Biodesix said this week that it has entered a partnership with UK-based genomics firm Inivata to develop and commercialize a next-generation sequencing-based blood test for clinical use in lung cancer.

The two companies are still in the early days of determining what intended uses to pursue under the collaboration, Biodesix CEO David Brunel told GenomeWeb. He cited as likely potential directions development of tests for guiding therapy in late-stage patients who have exhausted conventional treatment plans and support of drug development efforts.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.